The PTEN Study: Eligibility Criteria and Clinical Features Checklist

Please note that patient results will not be released until all required study documents and confirmatory records have been received.

If this information is not available to you for inclusion with the patient's sample and other required paperwork, please ensure that the institution(s) where these records may be found is listed on the medical release form so our research team can retrieve this information.

Also please note: whether macrocephaly is present or not, an OFC measurement is now a requirement for study participation. Our study will allow the following measurements to "count" as macrocephaly for adults:

Men: Minimum of 58.0 cm

• Women: Minimum of 57.3 cm

Eligibility Criteria

Patients with the following will automatically qualify for study participation:

- Known PTEN mutation or variant of uncertain significance
- Lhermitte-Duclos disease
- Pigmented macules of the glans penis
- Clinical diagnosis of Proteus or Proteus-like syndrome
- Adult patients with a score of 10 or greater per the Cleveland Clinic *PTEN* Risk Calculator (website: http://www.lerner.ccf.org/genomic-medicine/ccscore/)
- Pediatric patients with macrocephaly plus at least one of the following:
 - o Autism/mental retardation/developmental delay
 - o Lipoma, biopsy-proven trichilemmoma, oral papillomatosis, or hemangioma
 - o Arteriovenous malformation
 - One or more gastrointestinal polyp(s)

In addition, patients with the following combination of findings from our clinical features checklist will qualify for study participation:

- Two major criteria
- One major plus two minor criteria
- Three minor criteria

Exclusion Criteria

Please do not submit the following:

- Patients with genetic tests (i.e. BRCA testing) pending
- Patients with other diagnostic testing that explains their major features (example: patient has endometrial cancer, fibrocystic breast disease, and lipoma but also has deleterious *MSH2* mutation)
- Patients for whom pathology records are unattainable or at an unknown institution.

If you have a question about whether or not your patient qualifies for this study, please send a clinical summary and a copy of the pedigree to the study team for review by fax: (216) 636-0009 or email: pten@ccf.org.

CCF IRB #: IRB 8458 Approval Date: 9/23/2023 Expiration Date: 9/22/2024

The Cleveland Clinic

IRB 8458: Molecular Mechanisms Involved in Cancer Predisposition

Subject Consent to Contact Form

I have reviewed the information provided about the research study and I am interested in learning more. A representative from The Genomic Medicine Institute has permission to contact me regarding study participation.

Phone number: ()	Preferred days/times:
Alternate number: ()	Preferred days/times:
Today's date:	
Your signature:	
Print your name:	
If you are consenting on behalf of a child	(under 18 years old), please print the child's
name:	
Participant's date of birth:	
Contact information for health care provider faci	litating study participation:
Name:	Title:
Institution:	
E-mail:	Phone number: ()
Please mail this form to:	
The Cleveland Clinic Genomic Medicine Institute 9500 Euclid Avenue, R4 Cleveland, OH 44195	
<u>OR</u>	
FAX to:	
FAX #: (216) 636-0009 Attn: Beth Crouser, MBA	



AUTHORIZATION TO DISCLOSE HEALTH INFORMATION TO CLEVELAND CLINIC

1. Patient Information			
Name (First, Middle, Last)		Cleveland Clinic Medica	al Record # if known:
Current Address	City	State	Zip
Last 4 Digits of Social Security #	Email	Phone Number	r Date of Birth / /
2. Release Information From			
Facility/Provider:			
Address	City/State	Zip	Phone Number ()
3. Release Information To: CLEVELA			
Name of Recipient: Facility and/or Ma	^{il Code:} Beth Crouser; Genom	nic Medicine Inst	itute/R4
Address	City/State		Phone Number Fax Number (216) 445-5850 (216) 636-0009
Select one: Paper Secure elec	tronic delivery (If secure delivery, provid	e email): crouseb2@ccf.org	
Purpose of Disclosure:	☐ Continuity of Care	Other (please indicate)	Research Participatin
(Purpose for disclosure must be	completed prior to processing)		
Dates of service to release (FRO	OM)(T	0):	
Office Visits Emergency Department Reports Discharge Summary Operative Reports	History & Physical Other Chart Summary Consult Notes Laboratory Reports	X Tumor Bloo	est Results
indicated/described above. I understand and mental illness, HIV test results or di	named sending Facility/Provider as described and acknowledge that the requested he agnosis, treatment of AIDS/AIDS-related outpatient Psychotherapy Notes as defi	ealth information may co conditions, and/or alcoh	ntain information regarding physical ol/drug abuse. This authorization
representative) through written notice p	pire one year from the date of authorizate presented to above named Facility/Provinced in response to this authorization. I use or not I sign this authorization.	der as described in Sectio	on 2. Any revocation will not apply to
understand that the sender of my health inquiring about these potential charges.	, my information may be re-disclosed by h information may charge for the service d and dated, it may be returned and reso	of disclosing medical inf	ormation and I am responsible for
	//		
Signature of Patient/Patient's Personal Repr	esentative Print	ed Name	Date Signed
Relationship, if not Patient			

*Psychotherapy Notes are defined as notes that document private, joint, group, or family counseling sessions that are separated from the rest of a patient's medical records.

Submit completed request to the Cleveland Clinic Facility/Mailcode identified in Section 3 above.

NOTICE: If you send health information to Cleveland Clinic via email, please know that your message may be sent in an unencrypted email. An unencrypted email means there is a risk that the information in the email and any attachments could potentially be read by a third party when it is sent through the internet.

Revision: 10/2019

Banking Checklist: To be completed for all studies DOB: Subject Name: Date of blood draw: If CCF patient: CCF# MANDATORY Has another family member enrolled into any of our studies? (please circle one) Yes No -If so, what is the family member's first and last name: -What is this patient's relationship to the above family member: Subject Sex: ☐ Female MANDATORY ☐ Male Subject Race (check all that apply): ☐ American Indian and Alaska Native ☐ Black or African American □ Asian ☐ Native Hawaiian and Other Pacific Islander White
 White
 Note
 Not
 Not □ Other ☐ Hispanic or Latino ☐ Not Hispanic or Latino Subject Ethnicity: Country/countries of origin: Enrolling Healthcare Provider: Please note: patient results will be sent to this individual via confidential e-mail. Title: _____ Institution: _____ Phone: E-mail: • Check off each required document to signify that it is included • Check the box by the study/studies for which you are submitting a patient Required from IRB-approved outside sites: Required from non-IRB approved outside sites (most sites): ☐ Copy of signed informed consent form ☐ Contact information page ☐ Subject consent to contact form ☐ Authorization for release of medical ☐ Authorization for release of medical information information ☐ Pedigree ☐ Pedigree ☐ Copy of available records per study ☐ Informed consent process documentation form/ ☐ Copy of available records per study **DO NOT** send patient's sample with other forms required by enrolling site's IRB these documents. ☐ Patient sample in provided collection kit The PTEN Study ☐ Meets study criteria per checklist ☐ Participant does not fully meet study criteria, but pre-approval for participation has been obtained from genetic counselor study coordinator ☐ Family member of previous study participant Additional required documents: ☐ Completed PTEN Clinical Features Checklist The SDH Study – Additional required documents: ☐ Completed SDH Clinical Features Checklist The Velosano Study ☐ Clinic Note General Cancer Banking: If not a CCF patient, submission for this study was preapproved by the following research team member: ☐ Diagnosis: The U54 Autism Study ☐ Clinic Note

☐ Completed Questionnaires

The PTEN Study: Clinical Features Checklist, page 1 of 2

Patient Name:	DOB:	Gender:
Patient Height:	Patient Weight:	Patient OFC (in cm):

AQ = automatic qualification; M = major criteria; m = minor criteria; see revised eligibility criteria on above page to ensure your patient qualifies.

√if present	CNS Features	AQ/M/m	Documentation requested
	Lhermitte-Duclos disease	AQ	MRI and/or biopsy
	Macrocephaly	M	Clinic note
	Autism	m	Clinic note
	Mental retardation	m	Clinic note
	Developmental delay	m	Clinic note
/ if present	Endocrine Features	AQ/M/m	Documentation requested
	Thyroid cancer (not medullary)	M	Pathology report
	Goiter	m	Imaging
	Thyroid nodule(s)	m	Imaging
if present	Breast Features	AQ/M/m	Documentation requested
	Invasive carcinoma	M	Pathology report
	Ductal carcinoma in situ	m	Pathology report
	Lobular carcinoma in situ	m	Pathology report
	Breast papilloma	m	Pathology report
	Breast fibroadenoma	m	Pathology report
	Fibrocystic breast disease	m	Pathology report, imaging, and/or clinic note
J if present	Dermatologic Features	AQ/M/m	Documentation requested
	Pigmented macules of the glans penis	AQ	Clinic note
	Biopsy-proven trichilemmoma(s)	M	Pathology report
	Oral-mucosal papillomatosis	M	Clinic note
	Lipoma(s)	m	Pathology report
J if present	Cardiovascular Features	AQ/M/m	Documentation requested
	Arteriovenous malformation	m	Pathology report and/or imaging
J if present	Gastrointestinal Features	AQ/M/m	Documentation requested
	Hamartomatous (juvenile, Peutz- Jegher) polyp(s)	M	Pathology report
	Ganglioneuroma(s)	M	Pathology report
	Hyperplastic polyp(s)	m	Pathology report
	Glycogenic acanthosis	m	Endoscopy report
J if present	Genitourinary Features	AQ/M/m	Documentation requested
	Endometrial (uterine) cancer	M	Pathology report
	Uterine fibroid(s)	m	Pathology report and/or imaging
	Renal cell (kidney) cancer	m	Pathology report
	Congenital genitourinary defect	m	Imaging or clinic note
	Other genitourinary tumor (specify):	m	Pathology and/or imaging
J if present	Other Features	AQ/M/m	Documentation requested
	Clinical diagnosis of Proteus or Proteus-like syndrome	AQ	Clinic note

The PTEN Study: Clinical Features Checklist, page 2 of 2 Patient Name: _____ DOB: _____ Gender: _____

Other Findings: Please circle present (P), absent (A), or unknown (U) for each.

MRI-proven megencephaly	P	A	U		Dermatofibroma	P	Α	U
Malignant CNS tumor	P	A	U		Fibroma of other organ	P	Α	U
Benign CNS tumor	P	A	U	-	GI polyp other than listed previously	P	Α	U
Demyelinating leukodystrophy	P	A	U		Colon cancer	P	Α	U
Hemangioma of skin	P	A	U		Other GI malignancy	P	Α	U
Hemangioma of other organ	P	Α	U		Melanoma	P	Α	U
Acral keratoses	P	Α	U	17	Other malignant skin cancer	P	Α	U
"Skin tags", pathology unknown	P	Α	U		Hearing loss	P	Α	U
Hashimoto's (chronic lymphocytic)	P	A	U		Other invasive cancer(s)	P	A	U
thyroiditis				13	Specify:			

Other History: Please circle yes (Y) or no (N) to indicate whether or not the patient has undergone the following:

Brain CT	Y	N	Breast mammogram	Y	N
Brain MRI	Y	N	Breast ultrasound	Y	N
Brain biopsy	Y	N	Breast MRI	Y	N
Thyroid ultrasound	Y	N	Breast biopsy	Y	N
Other thyroid scan:	Y	N	Breast lumpectomy	Y	N
Thyroid FNA	Y	N	Unilateral mastectomy	Y	N
Partial thyroidectomy	Y	N	Bilateral mastectomy	Y	N
Total thyroidectomy	Y	N	Hysterectomy	Y	N
Abdominal ultrasound	Y	N	Unilateral oophorectomy	Y	N
Abdominal CT	Y	N	Bilateral oophorectomy	Y	N
Abdominal MRI	Y	N	CT Angiography (specify organ):	Y	N
Pelvic ultrasound	Y	N			
Pelvic CT	Y	N	MR Angiography (specify organ):	Y	N
Pelvic MRI	Y	N		_	
Colonoscopy	Y	N	Biopsy of other organ(s):	Y	N
EGD/Upper endoscopy	Y	N			
Partial colectomy	Y	N	Other scans or procedures not listed here:	Y	N
Total colectomy	Y	N			
Biopsy of any skin lesion	Y	N			

<u>Other Testing:</u> Please check to indicate whether or not the patient has had any of the following genetic tests and give results. Please include a copy of the lab report for any tests that have been done.

J	Test name	Result	THE RESERVE	
	BRCA1/2 sequencing and 5-site rearrangement panel	☐ Positive	☐ Negative	☐ VUS
	BRCA1/2 Multisite-3 panel	☐ Positive	☐ Negative	
	BART	☐ Positive	☐ Negative	□ VUS
	Chromosome analysis (Karyotype or array)	☐ Abnormal	□ Normal	□ VUS
	Clinical PTEN sequencing	☐ Positive	☐ Negative	☐ VUS
	Clinical PTEN MLPA	☐ Positive	☐ Negative	□ VUS
	Clinical PTEN promoter analysis	☐ Positive	☐ Negative	□ VUS
	Fragile X testing	☐ Positive	☐ Negative	□ VUS
	MSI testing	☐ High	☐ Stable	☐ Low
	IHC analysis	☐ Positive	☐ Negative	☐ Equivocal
	Other gene testing (specify):	☐ Positive	☐ Negative	□ VUS
	Other gene testing (specify):	☐ Positive	☐ Negative	□ VUS

CLEVELAND CLINIC FOUNDATION --- MEDICAL GENETICS FAMILY HISTORY

Name:	CCF#:	DOB:	DOV:
G G * Goiter, nodules, Hashimoto * Trichilemmoma, acral keratosis, skin tags, lipoma, penile macules, oral-mucosal papillomas, lipoma		□ □ Esophagus (glycogenic acanthosis) □ □ Seizures □ □ Congenital G/U defects □ □ Other Dx running in Family	Y N Macrocephaly Autism/MR/DD Psychiatric d/o Thyroid * Pheo/PGL/Adrenal tumor NOS Pheo/PGL/Adrenal tumor NOS Renign breast Dz (Fibrocystic) National Hamiltonid Autism/Macrocephaly Renile macules AvM/hemangloma U Lhermitte-Duclos Dz Gl polyos (Jocation/fyrpe)